A Phase 1 interventional study of SRP-4045 and Placebo in Duchenne Muscular Dystrophy, sponsored by Sarepta Therapeutics, Inc.. Completed at 3 sites in United States. Open to male participants aged 7 Years to 21 Years. Per ClinicalTrials.gov, last updated 2021-05-17.
Sponsored by Sarepta Therapeutics, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. — 5 open to participants now, 6 under way, 2 of them phase 3. Muscular Dystrophy, Duchenne · Sarepta Therapeutics, Inc..
Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., this one is the 20th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2015, is one of 5 in phase 1, and was the 9th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →5 of the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. are open now, in 9 countries. Recruiting first, the newest first:
Sarepta Therapeutics, Inc. · Sites in United States
Ages 4+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States
Ages 2+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States
Ages 4+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States, Belgium, Germany and 6 more countries
Men only
Sarepta Therapeutics, Inc. · Sites in United States
Men only
By country, each count listing its studies:
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 7 Years to 21 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 7 · Phase 4 1
First in 2009; this study’s year is marked. 3 started in 2015.
This study's enrollment of 12 is below the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 24 across the 25 interventional studies, 400 across the 2 observational. Of the 21 that completed or were terminated, 15 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sarepta Therapeutics, Inc. is the lead sponsor of 52 studies on the registry; 8 are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.
2 of the studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT07542314Sarepta Therapeutics, Inc.Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a first-in-human dose-titration and open-label extension study to assess safety, tolerability, and pharmacokinetics of SRP-4045 in advanced-stage Duchenne muscular dystrophy (DMD) patients with deletions amenable to exon 45 skipping.
This is a randomized, placebo-controlled dose-titration study to assess safety, tolerability, and pharmacokinetics of 4 dose levels of SRP-4045 in genotypically confirmed advanced-stage DMD patients with deletions amenable to exon 45 skipping.
After completion of the dose-titration portion of the study and SRP-4045 is determined to be safe, all patients will be evaluated on open-label SRP-4045 for the duration of the study.
Safety, including adverse event monitoring, routine laboratory assessments, and cardiac testing will be monitored through the duration of the dose-titration and open-label portions of the study.
Clinical efficacy will be assessed at regularly scheduled study visits via quality of life questionnaires and tests of pulmonary and upper extremity function through the duration of the dose-titration and open-label portions of the trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other inclusion/exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with genotypically confirmed Duchenne muscular dystrophy (DMD) characterized by deletions amenable to exon 45 skipping will receive placebo-matching to casimersen intravenous (IV) infusions, once weekly over approximately 12 weeks in the double-blind period.
Drug: Placebo
Participants with genotypically confirmed DMD characterized by deletions amenable to exon 45 skipping will receive weekly IV infusions of casimersen at four escalating dose levels, each for at least 2 weeks: 4 milligrams per kilograms (mg/kg) during Week 1 to Week 2, followed by 10 mg/kg during Week 3 to Week 4, followed by 20 mg/kg during Week 5 to Week 6, followed by 30 mg/kg beginning at Week 7 and continue over approximately Week 12 in the double-blind period.
Drug: SRP-4045
All participants who completed double blind period will be enrolled to receive casimersen 30 mg/kg once weekly, for up to Week 144 in the open label extension period.
Drug: SRP-4045
SRP-4045 solution for IV infusion.
SRP-4045 placebo-matching solution for IV infusion.
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Adverse event (AE) was any untoward medical occurrence in a clinical trial participant, which does not necessarily have a causal relationship with the investigational drug. AEs also included abnormal physical examination findings (Physical examination were conducted per protocol and any clinically significant abnormal findings were recorded in medical history if pre-existing or addressed as an AE if new or worsening). TEAEs was defined as AEs that started, worsened, or became serious on or after the start of first infusion through 148 weeks. Number of participants with TEAEs were reported.
Time frame: Baseline up to Week 148
Number of Participants With Potentially Clinically Significant (PCS) Laboratory Abnormalities Reported as TEAEs
Laboratory parameters included serum chemistry (hepatic chemistry and renal chemistry), hematology, coagulation, and urinalysis. Number of participants with potentially clinically significant abnormal finding were reported as TEAEs. The Investigator determined whether abnormal assessment results were potentially clinically significant or not. Potentially clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care.
Time frame: Baseline up to Week 148
Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs Reported as TEAEs
Vital sign parameters included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and body temperature. Number of participants with at least one potentially clinically significant abnormal vital signs findings were reported as TEAEs. The Investigator determined whether abnormal assessment results were potentially clinically significant or not. Potential clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care.
Time frame: Baseline up to Week 148
Number of Participants With Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) Reported as TEAEs
Twelve-lead ECGs were performed at a consistent time of day throughout the study. Electrocardiograms were performed only after the participant was in the supine position, resting, and quiet for a minimum of 15 minutes. The ECG was manually reviewed and interpreted by medically qualified personnel. Number of participants with potentially clinically significant abnormalities in ECG reported as TEAEs were presented here. The Investigator determined whether abnormal assessment results were potentially clinically significant or not.
Time frame: Baseline up to Week 148
Number of Participants With Potentially Clinically Significant Abnormalities in Echocardiograms (ECHO)
Standard, 2-dimensional ECHOs were performed at a consistent time of day throughout the study.The ECHO was reviewed and interpreted by medically qualified personnel. Number of participants with potentially clinically significant abnormalities in ECHO were reported.
Time frame: Baseline up to Week 148
Maximum Plasma Concentration (Cmax) of Casimersen
Maximum Concentration (Cmax) of casimersen in plasma was evaluated.
Time frame: Pre-infusion, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 (for 30 mg/kg arm) in DBP and Week 60 (for 30 mg/kg arm) in OLEP
Time to Reach Maximum Plasma Concentration (Tmax) of Casimersen
Time to reach maximum plasma concentration (Tmax) of casimersen was evaluated.
Time frame: Pre-infusion, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 (for 30 mg/kg arm) in DBP and Week 60 (for 30 mg/kg arm) in OLEP
Area Under Concentration-time Curve From Time of Dosing to the Last Measurable Concentration (AUClast) of Casimersen in Plasma
Area under the concentration-time curve from time zero to the last quantifiable concentration of casimersen in plasma were evaluated.
Time frame: Pre-infusion, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 (for 30 mg/kg arm) in DBP and Week 60 (for 30 mg/kg arm) in OLEP
Area Under Concentration-Time Curve From Time Zero Pre-dose to Twenty-Four Hours Post-dose (AUC0-24) of Casimersen in Plasma
Area under concentration-time curve from time zero pre-dose to twenty-four hours post-dos of casimersen in plasma were evaluated.
Time frame: Pre-infusion, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 (for 30 mg/kg arm) in DBP and Week 60 (for 30 mg/kg arm) in OLEP
Area Under the Concentration-Time Curve From Time Zero Extrapolated to the Infinity (AUCinf) of Casimersen in Plasma
Area under the concentration-time curve from time zero extrapolated to the infinity of casimersen in plasma was evaluated.
Time frame: Pre-infusion, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 (for 30 mg/kg arm) in DBP and Week 60 (for 30 mg/kg arm) in OLEP
Apparent Volume of Distribution at Steady State (Vss) of Casimersen
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution at steady state of casimersen was evaluated.
Time frame: Pre-infusion, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 (for 30 mg/kg arm) in DBP and Week 60 (for 30 mg/kg arm) in OLEP
Elimination Half-life (T1/2) of Casimersen
T1/2 is the time measured for the plasma concentration of drug to decrease by one half. T1/2 of casimersen was evaluated.
Time frame: Pre-infusion, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 (for 30 mg/kg arm) in DBP and Week 60 (for 30 mg/kg arm) in OLEP
Total Clearance (CL) of Casimersen
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. CL of casimersen was evaluated.
Time frame: Pre-infusion, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 (for 30 mg/kg arm) in DBP and Week 60 (for 30 mg/kg arm) in OLEP
Mean Residence Time Extrapolated to Infinity (MRTinf) of Casimersen
MRTinf = AUMCinf/AUCinf - T/2, where T was the infusion duration, and AUMCinf was the area under the first moment curve from time 0 extrapolated to infinite time, calculated using the linear/log trapezoidal method. MRTinf of casimersen was evaluated.
Time frame: Pre-infusion, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 (for 30 mg/kg arm) in DBP and Week 60 (for 30 mg/kg arm) in OLEP
Double-Blind Period: Renal Clearance (CLR) of Casimersen
Renal clearance was calculated using the partial AUC0-24 from the non-compartmental analysis in plasma and AE0-24. AUC0-24 was defined as area under the plasma concentration-time curve, from time 0 to 24 hours after completion of dosing. AE0-24 was defined as total cumulative amount excreted from 0 to 24 hours. Summarized data of all urine collection intervals are reported.
Time frame: 0 to 4, 4 to 8, 8 to 12, and 12 to 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 and 12 (for 30 mg/kg arm) in double-blind period
The study was conducted at 3 sites in United States.
| Milestone | Double-Blind Period: Placebo | Double-Blind Period: Casimersen | Open Label Extension Period: Casimersen |
|---|---|---|---|
| Started | 4 | 8 | 0 |
| Received 4 mg/kg | 0 | 8 | 0 |
| Received 10 mg/kg | 0 | 8 | 0 |
| Received 20 mg/kg | 0 | 8 | 0 |
| Received 30 mg/kg | 0 | 8 | 0 |
| Completed | 4 | 8 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Double-Blind Period: Placebo | Double-Blind Period: Casimersen | Open Label Extension Period: Casimersen |
|---|---|---|---|
| Started | 0 | 0 | 12 |
| Completed | 0 | 0 | 11 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
Adverse event (AE) was any untoward medical occurrence in a clinical trial participant, which does not necessarily have a causal relationship with the investigational drug. AEs also included abnormal physical examination findings (Physical examination were conducted per protocol and any clinically significant abnormal findings were recorded in medical history if pre-existing or addressed as an AE if new or worsening). TEAEs was defined as AEs that started, worsened, or became serious on or after the start of first infusion through 148 weeks. Number of participants with TEAEs were reported.
| Participants | Double-Blind Period: Placebo | Double-Blind Period: Casimersen 4 mg/kg | Double-Blind Period: Casimersen 10 mg/kg | Double-Blind Period: Casimersen 20 mg/kg | Double-Blind Period: Casimersen 30 mg/kg | Open Label Extension Period: Casimersen 30 mg/kg |
|---|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 4 | 5 | 3 | 3 | 7 | 12 |
Laboratory parameters included serum chemistry (hepatic chemistry and renal chemistry), hematology, coagulation, and urinalysis. Number of participants with potentially clinically significant abnormal finding were reported as TEAEs. The Investigator determined whether abnormal assessment results were potentially clinically significant or not. Potentially clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care.
| Participants | Double-Blind Period: Placebo | Double-Blind Period: Casimersen 4 mg/kg | Double-Blind Period: Casimersen 10 mg/kg | Double-Blind Period: Casimersen 20 mg/kg | Double-Blind Period: Casimersen 30 mg/kg | Open Label Extension Period: Casimersen 30 mg/kg |
|---|---|---|---|---|---|---|
| Serum chemistry: Hepatic chemistry | 0 | 0 | 0 | 0 | 0 | 0 |
| Serum chemistry: Renal chemistry | 0 | 0 | 0 | 0 | 0 | 0 |
| Hematolgy: Leukocytes | 0 | 0 | 0 | 0 | 2 | 4 |
| Hematolgy: Neutrophils | 0 | 0 | 0 | 0 | 4 | 6 |
| Coagulation: Platelet count | 0 | 0 | 0 | 0 | 2 | 2 |
| Urinalysis | 0 | 0 | 0 | 0 | 0 | 1 |
Vital sign parameters included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and body temperature. Number of participants with at least one potentially clinically significant abnormal vital signs findings were reported as TEAEs. The Investigator determined whether abnormal assessment results were potentially clinically significant or not. Potential clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care.
| Participants | Double-Blind Period: Placebo | Double-Blind Period: Casimersen 4 mg/kg | Double-Blind Period: Casimersen 10 mg/kg | Double-Blind Period: Casimersen 20 mg/kg | Double-Blind Period: Casimersen 30 mg/kg | Open Label Extension Period: Casimersen 30 mg/kg |
|---|---|---|---|---|---|---|
| Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs Reported as TEAEs | 0 | 0 | 0 | 0 | 1 | 1 |
Twelve-lead ECGs were performed at a consistent time of day throughout the study. Electrocardiograms were performed only after the participant was in the supine position, resting, and quiet for a minimum of 15 minutes. The ECG was manually reviewed and interpreted by medically qualified personnel. Number of participants with potentially clinically significant abnormalities in ECG reported as TEAEs were presented here. The Investigator determined whether abnormal assessment results were potentially clinically significant or not.
| Participants | Double-Blind Period: Placebo | Double-Blind Period: Casimersen 4 mg/kg | Double-Blind Period: Casimersen 10 mg/kg | Double-Blind Period: Casimersen 20 mg/kg | Double-Blind Period: Casimersen 30 mg/kg | Open Label Extension Period: Casimersen 30 mg/kg |
|---|---|---|---|---|---|---|
| Number of Participants With Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) Reported as TEAEs | 0 | 0 | 0 | 0 | 0 | 1 |
Standard, 2-dimensional ECHOs were performed at a consistent time of day throughout the study.The ECHO was reviewed and interpreted by medically qualified personnel. Number of participants with potentially clinically significant abnormalities in ECHO were reported.
| Participants | Double-Blind Period: Placebo | Double-Blind Period: Casimersen 4 mg/kg | Double-Blind Period: Casimersen 10 mg/kg | Double-Blind Period: Casimersen 20 mg/kg | Double-Blind Period: Casimersen 30 mg/kg | Open Label Extension Period: Casimersen 30 mg/kg |
|---|---|---|---|---|---|---|
| Number of Participants With Potentially Clinically Significant Abnormalities in Echocardiograms (ECHO) | 0 | 0 | 0 | 0 | 0 | 0 |
Maximum Concentration (Cmax) of casimersen in plasma was evaluated.
| Nanogram per milliliter (ng/mL) | Double-Blind Period: Casimersen 4 mg/kg | Double-Blind Period: Casimersen 10 mg/kg | Double-Blind Period: Casimersen 20 mg/kg | Double-Blind Period: Casimersen 30 mg/kg | Open Label Extension Period: Casimersen 30 mg/kg |
|---|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of Casimersen | 13700 ± 25.0 | 39400 ± 11.7 | 64400 ± 27.4 | 119000 ± 33.6 | 115000 ± 31.5 |
Time to reach maximum plasma concentration (Tmax) of casimersen was evaluated.
| Hour | Double-Blind Period: Casimersen 4 mg/kg | Double-Blind Period: Casimersen 10 mg/kg | Double-Blind Period: Casimersen 20 mg/kg | Double-Blind Period: Casimersen 30 mg/kg | Open Label Extension Period: Casimersen 30 mg/kg |
|---|---|---|---|---|---|
| Time to Reach Maximum Plasma Concentration (Tmax) of Casimersen | 1.11 (0.92 to 1.22) | 1.03 (0.93 to 1.17) | 1.03 (0.83 to 1.22) | 0.94 (0.83 to 1.18) | 0.95 (0.78 to 1.08) |
Area under the concentration-time curve from time zero to the last quantifiable concentration of casimersen in plasma were evaluated.
| Hour*nanogram per milliliter (hr*ng/mL) | Double-Blind Period: Casimersen 4 mg/kg | Double-Blind Period: Casimersen 10 mg/kg | Double-Blind Period: Casimersen 20 mg/kg | Double-Blind Period: Casimersen 30 mg/kg | Open Label Extension Period: Casimersen 30 mg/kg |
|---|---|---|---|---|---|
| Area Under Concentration-time Curve From Time of Dosing to the Last Measurable Concentration (AUClast) of Casimersen in Plasma | 23100 ± 29.5 | 59500 ± 16.2 | 101000 ± 17.7 | 188000 ± 27.4 | 182000 ± 33.8 |
Area under concentration-time curve from time zero pre-dose to twenty-four hours post-dos of casimersen in plasma were evaluated.
| h*ng/mL | Double-Blind Period: Casimersen 4 mg/kg | Double-Blind Period: Casimersen 10 mg/kg | Double-Blind Period: Casimersen 20 mg/kg | Double-Blind Period: Casimersen 30 mg/kg | Open Label Extension Period: Casimersen 30 mg/kg |
|---|---|---|---|---|---|
| Area Under Concentration-Time Curve From Time Zero Pre-dose to Twenty-Four Hours Post-dose (AUC0-24) of Casimersen in Plasma | 23200 ± 29.4 | 59500 ± 16.1 | 101000 ± 17.7 | 188000 ± 27.4 | 182000 ± 33.8 |
Area under the concentration-time curve from time zero extrapolated to the infinity of casimersen in plasma was evaluated.
| h*ng/mL | Double-Blind Period: Casimersen 4 mg/kg | Double-Blind Period: Casimersen 10 mg/kg | Double-Blind Period: Casimersen 20 mg/kg | Double-Blind Period: Casimersen 30 mg/kg | Open Label Extension Period: Casimersen 30 mg/kg |
|---|---|---|---|---|---|
| Area Under the Concentration-Time Curve From Time Zero Extrapolated to the Infinity (AUCinf) of Casimersen in Plasma | 23300 ± 29.5 | 58300 ± 16.0 | 101000 ± 17.7 | 189000 ± 27.5 | 182000 ± 33.9 |
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution at steady state of casimersen was evaluated.
| Liter per kilogram (L/kg) | Double-Blind Period: Casimersen 4 mg/kg | Double-Blind Period: Casimersen 10 mg/kg | Double-Blind Period: Casimersen 20 mg/kg | Double-Blind Period: Casimersen 30 mg/kg | Open Label Extension Period: Casimersen 30 mg/kg |
|---|---|---|---|---|---|
| Apparent Volume of Distribution at Steady State (Vss) of Casimersen | 0.369 ± 24.4 | 0.343 ± 12.5 | 0.407 ± 23.4 | 0.319 ± 31.4 | 0.367 ± 28.9 |
T1/2 is the time measured for the plasma concentration of drug to decrease by one half. T1/2 of casimersen was evaluated.
| Hour | Double-Blind Period: Casimersen 4 mg/kg | Double-Blind Period: Casimersen 10 mg/kg | Double-Blind Period: Casimersen 20 mg/kg | Double-Blind Period: Casimersen 30 mg/kg | Open Label Extension Period: Casimersen 30 mg/kg |
|---|---|---|---|---|---|
| Elimination Half-life (T1/2) of Casimersen | 2.92 ± 0.985 | 3.29 ± 0.640 | 3.71 ± 0.616 | 3.82 ± 0.741 | 3.45 ± 0.359 |
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. CL of casimersen was evaluated.
| Liters per hour per kilogram (L/h/kg) | Double-Blind Period: Casimersen 4 mg/kg | Double-Blind Period: Casimersen 10 mg/kg | Double-Blind Period: Casimersen 20 mg/kg | Double-Blind Period: Casimersen 30 mg/kg | Open Label Extension Period: Casimersen 30 mg/kg |
|---|---|---|---|---|---|
| Total Clearance (CL) of Casimersen | 0.177 ± 29.1 | 0.181 ± 15.9 | 0.205 ± 18.5 | 0.163 ± 27.7 | 0.180 ± 35.0 |
MRTinf = AUMCinf/AUCinf - T/2, where T was the infusion duration, and AUMCinf was the area under the first moment curve from time 0 extrapolated to infinite time, calculated using the linear/log trapezoidal method. MRTinf of casimersen was evaluated.
| Hour | Double-Blind Period: Casimersen 4 mg/kg | Double-Blind Period: Casimersen 10 mg/kg | Double-Blind Period: Casimersen 20 mg/kg | Double-Blind Period: Casimersen 30 mg/kg | Open Label Extension Period: Casimersen 30 mg/kg |
|---|---|---|---|---|---|
| Mean Residence Time Extrapolated to Infinity (MRTinf) of Casimersen | 2.08 ± 13.5 | 1.89 ± 16.1 | 1.98 ± 12.7 | 1.96 ± 16.6 | 2.04 ± 10.3 |
Renal clearance was calculated using the partial AUC0-24 from the non-compartmental analysis in plasma and AE0-24. AUC0-24 was defined as area under the plasma concentration-time curve, from time 0 to 24 hours after completion of dosing. AE0-24 was defined as total cumulative amount excreted from 0 to 24 hours. Summarized data of all urine collection intervals are reported.
| L/h/kg | Double-Blind Period: Casimersen 4 mg/kg | Double-Blind Period: Casimersen 10 mg/kg | Double-Blind Period: Casimersen 20 mg/kg | Double-Blind Period: Casimersen 30 mg/kg |
|---|---|---|---|---|
| Double-Blind Period: Renal Clearance (CLR) of Casimersen | 0.137 ± 25.8 | 0.162 ± 22.6 | 0.209 ± 29.0 | 0.177 ± 34.2 |
Collected over From start of study drug administration up to Week 148. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-Blind Period: Placebo | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Double-Blind Period: Casimersen 4 mg/kg | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| Double-Blind Period: Casimersen 10 mg/kg | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Double-Blind Period: Casimersen 20 mg/kg | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Double-Blind Period: Casimersen 30 mg/kg | 0/8 (0%) | 1/8 (12.5%) | 7/8 (87.5%) |
| Open Label Extension Period: Casimersen 30 mg/kg | 0/12 (0%) | 3/12 (25%) | 12/12 (100%) |
| Event | Double-Blind Period: Placebo | Double-Blind Period: Casimersen 4 mg/kg | Double-Blind Period: Casimersen 10 mg/kg | Double-Blind Period: Casimersen 20 mg/kg | Double-Blind Period: Casimersen 30 mg/kg | Open Label Extension Period: Casimersen 30 mg/kg |
|---|---|---|---|---|---|---|
| Septic embolusInfections and infestations | 0/4 | 0/8 | 0/8 | 0/8 | 1/8 | 1/12 |
| vena cava thrombosisVascular disorders | 0/4 | 0/8 | 0/8 | 0/8 | 1/8 | 1/12 |
| bacteraemiaInfections and infestations | 0/4 | 0/8 | 0/8 | 0/8 | 1/8 | 1/12 |
| Femur fractureInjury, poisoning and procedural complications | 0/4 | 0/8 | 0/8 | 0/8 | 0/8 | 1/12 |
| Tibia fractureInjury, poisoning and procedural complications | 0/4 | 0/8 | 0/8 | 0/8 | 0/8 | 1/12 |
| Event | Double-Blind Period: Placebo | Double-Blind Period: Casimersen 4 mg/kg | Double-Blind Period: Casimersen 10 mg/kg | Double-Blind Period: Casimersen 20 mg/kg | Double-Blind Period: Casimersen 30 mg/kg | Open Label Extension Period: Casimersen 30 mg/kg |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 1/4 | 1/8 | 0/8 | 0/8 | 1/8 | 9/12 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 2/4 | 0/8 | 0/8 | 0/8 | 0/8 | 2/12 |
| Procedural painInjury, poisoning and procedural complications | 1/4 | 0/8 | 0/8 | 2/8 | 3/8 | 4/12 |
| VomitingGastrointestinal disorders | 0/4 | 0/8 | 0/8 | 2/8 | 2/8 | 4/12 |
| HeadacheNervous system disorders | 0/4 | 1/8 | 0/8 | 0/8 | 2/8 | 4/12 |
| Upper respiratory tract infectionInfections and infestations | 0/4 | 0/8 | 0/8 | 0/8 | 0/8 | 4/12 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/4 | 0/8 | 0/8 | 0/8 | 0/8 | 4/12 |
| NauseaGastrointestinal disorders | 0/4 | 1/8 | 1/8 | 1/8 | 0/8 | 3/12 |
| Tinea versicolourInfections and infestations | 1/4 | 0/8 | 0/8 | 0/8 | 0/8 | 1/12 |
| Ligament sprainInjury, poisoning and procedural complications | 1/4 | 0/8 | 0/8 | 0/8 | 0/8 | 0/12 |
Safety set included all randomized participants who received at least 1 dose of study drug (casimersen or placebo) in double-blind period.
| Age, Continuous(Years) | Double-Blind Period: Placebo | Double-Blind Period: Casimersen | Total |
|---|---|---|---|
| Mean | 12.0 ± 2.16 | 14.4 ± 3.29 | 13.6 ± 3.09 |
| Sex: Female, Male(Participants) | Double-Blind Period: Placebo | Double-Blind Period: Casimersen | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 4 | 8 | 12 |
| Ethnicity (NIH/OMB)(Participants) | Double-Blind Period: Placebo | Double-Blind Period: Casimersen | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 4 | 7 | 11 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Double-Blind Period: Placebo | Double-Blind Period: Casimersen | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 4 | 6 | 10 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2015 to primary completion in Oct 2018, 35 months.
Results were first posted in May 2021, 2 years 7 months after primary completion.
Of 28 phase 1 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's 35 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Casimersen
Muscular Dystrophy, Duchenne →